BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource ...

FOSTER CITY, Calif., March 27, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that its partner, Takeda Pharmaceutical Company Limited, has received approval by the ...

On January 24, 2022, the IRS issued proposed regulations that impact certain elections available to U.S. taxpayers with respect to their indirect interests in passive foreign investment companies ...

Please provide your email address to receive an email when new articles are posted on . In a Healio video exclusive, Pam Vig, PhD, highlights new data on Livmarli for the treatment of patients with ...

Is it time to rethink your offshore PFIC investment(s)? What is a PFIC and why should you be concerned about the impact it will have upon taxation? Why should investment in a PFIC concern you as a US ...

With Livmarli sales reaching $142 million during its second full year on the market, Mirum Pharmaceuticals’ rare liver disease treatment is off to a solid start in fulfilling its blockbuster potential ...

Forbes contributors publish independent expert analyses and insights. Matthew Roberts is a tax attorney who covers tax litigation and fraud. The passive foreign investment company (PFIC) rules are ...

BOSTON, June 03, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today presented clinical data from its ...

Proposed regulations issued by the IRS on Thursday would clarify the circumstances under which investment income earned by a foreign insurance company is derived in the active conduct of an insurance ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Michael Boyle is an experienced financial ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...